Skin Cancer News

Melanoma: FDA Approves Adjuvant Dabrafenib With Trametinib

Melanoma: FDA Approves Adjuvant Dabrafenib With Trametinib

The FDA based its approval on the results of the phase 3 COMBI-AD study.

SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck

SLNBs Feasible After Wide Local Excisions in Melanoma of the Head and Neck

Sentinel nodes were accurately identified in all 30 patients who underwent WLE.

Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma

Adjuvant Pembrolizumab Reduces Risk of Recurrence in Stage III Melanoma

Improvement in RFS was seen regardless of PD-L1 status.

Nivolumab With/Without Ipilimumab Active in Melanoma Brain Metastases

Nivolumab With/Without Ipilimumab Active in Melanoma Brain Metastases

Grade 3 to 4 adverse events were observed in 54% (19), 16% (4), and 13% (2) of patients in Cohorts A, B, and C, respectively.

Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma

Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma

One death possibly related to treatment was, however, noted in the combination group.

Selumetinib Plus Dacarbazine Does Not Improve Uveal Melanoma Outcomes

Selumetinib Plus Dacarbazine Does Not Improve Uveal Melanoma Outcomes

Researchers randomly assigned 129 patients with previously untreated metastatic uveal melanoma to receive dacarbazine plus selumetinib or placebo.

One-time Fluorouracil Course May Reduce Risk of Squamous Cell Carcinoma

One-time Fluorouracil Course May Reduce Risk of Squamous Cell Carcinoma

A 75% reduction in SCC risk was observed among patients in the fluorouracil arm vs the placebo-arm.

Pembrolizumab May Cure Metastatic Melanoma in A Subset of Patients

Pembrolizumab May Cure Metastatic Melanoma in A Subset of Patients

Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.

FDA Grants Priority Review to Dabrafenib and Trametinib Combination for Resected Melanoma

FDA Grants Priority Review to Dabrafenib and Trametinib Combination for Resected Melanoma

The drug combination was studied in patients with BRAFV600E/K mutations in the phase 3 COMBI-AD study, the results of which led to the FDA's Priority Review designation.

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Melatonin Analogues May Have Antitumor Properties in Melanoma and Breast Cancer

Previous studies have demonstrated that melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.

Study Reveals Widespread Non-compliance With Indoor Tanning Regulations

Study Reveals Widespread Non-compliance With Indoor Tanning Regulations

Four hundred and twenty-seven tanning salons were contacted; 32.7% of contacted salons were non-compliant with their respective state's regulations.

FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma

FDA Grants Breakthrough Therapy Designation to Adjuvant Dabrafenib Plus Trametinib for Melanoma

Dabrafenib plus trametinib is the first adjuvant therapy indicated specifically for melanoma with the BRAFV600 mutation.

Study Reveals Factors Associated With Delays in Melanoma Treatment

Study Reveals Factors Associated With Delays in Melanoma Treatment

Researchers evaluated data from 7629 patients with melanoma included in the North Carolina cancer registry to determine relevant variables associated with delayed surgery.

ctDNA Sequencing Predicts Likelihood of Immunotherapy Response

ctDNA Sequencing Predicts Likelihood of Immunotherapy Response

Researchers collected ctDNA samples from patients with varying cancer types to determine whether liquid biopsies may help to predict response to checkpoint inhibition.

Propranolol May Prolong Disease-free Survival in Melanoma

Propranolol May Prolong Disease-free Survival in Melanoma

Previous studies demonstrated that propranolol may inhibit angiogenesis and migration of cancer cells, leading to a delay in disease progression.

Adjuvant Therapy With Dabrafenib Plus Trametinib May Provide Benefit in Melanoma

Adjuvant Therapy With Dabrafenib Plus Trametinib May Provide Benefit in Melanoma

Investigators randomly assigned 870 patients with advanced melanoma who had undergone complete resection to receive trametinib and dabrafenib vs placebo for 1 year.

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

Nivolumab Superior to Ipilimumab for Melanoma Recurrence Prevention

The randomized phase 3 CheckMate 238 trial evaluated the safety and efficacy of nivolumab vs ipilimumab in the resected stage III/IV melanoma setting.

FDA Grants Cemiplimab Breakthrough Therapy Designation for Cutaneous SCC

FDA Grants Cemiplimab Breakthrough Therapy Designation for Cutaneous SCC

CSCC has the second highest mortality rate among skin cancers after melanoma.

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Benefit of Binimetinib Addition to Encorafenib Confirmed in Melanoma

Binimetinib a BRAF inhibitor, improved objective response rate (ORR) and progression-free survival (PFS) among patients with BRAF-mutant melanoma.

Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma

Pembrolizumab Prolongs Overall Survival Compared With Ipilimumab in Melanoma

After the second interim analysis, an external data monitoring committee recommended that pembrolizumab be made available to patients receiving ipilimumab whose disease had progressed despite treatment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs